검색어: summary of ranking (덴마크어 - 핀란드어)

summary of resources 4.1 .
summary of resources 4.1 .

note for guidance on summary of requirements for active substances in part ii of the dossier
note for guidance on summary of requirements for active substances in part ii of the dossier

titel på dokumentet antimicrobials for veterinary use summary of product characteristics for antimicrobial products ectoparasiticide guidance for sheep, cattle and goats fluid therapy
asiakirjan nimi antimicrobials for veterinary use summary of product characteristics for antimicrobial products ectoparasiticide guidance for sheep, cattle and goats fluid therapy

titel på dokumentet antimicrobials for general use in target animal species summary of product characteristics for antimicrobial products efficacy requirements for ectoparasiticides for cattle fluid therapy
asiakirjan nimi antimicrobials for general use in target animal species summary of product characteristics for antimicrobial products efficacy requirements for ectoparasiticides for cattle fluid therapy

prospective planning of pharmacovigilance notice to applicants – guideline on the summary of product characteristics (ec december 1999 – revised version)
prospective planning of pharmacovigilance notice to applicants – guideline on the summary of product characteristics (ec december 1999 – revised version)

summary of questions and options - annex to the interim report on the european monetary system - ( heyveart report no. 39 )
summary of questions and options - annex to the interim report on the european monetary system - ( heyveart report no. 39 )

grundlag af den forelagte dokumentation, den faglige drøftelse i udvalget og den foreslåede ordlyd i den ajourførte udgave af guideline on summary of product characteristics fra oktober 2005 og den seneste qrd- model,
2005

på grund af den betydning, som adækvat smertebehandling af moderen må tillægges, kan chmp i overensstemmelse med "guideline on summary of product characteristics" tilslutte sig, at den forslåede tekst forbliver i pkt.
tämä tarkoittaa, että valmistetta voidaan antaa imettäville äideille, mutta imetys on keskeytettävä fentanyylilaastareiden käytön ajaksi, ja imetystä saa jatkaa aikaisintaan 72 tuntia laastarin poistamisen jälkeen.

grundlag af den forelagte dokumentation, den faglige drøftelse i udvalget og den foreslåede ordlyd i den ajourførte udgave af guideline on summary of product characteristics fra oktober 2005 og de seneste qrd- modeller (version 7),
2005

core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use – addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti- d immunoglobulin for intravenous and/ or intramuscular use (cpmp/ bpwg/ 574/ 99)
core summary of product characteristics for hepatitis b immunoglobulin revision of core summary of product characteristics for human normal immunoglobulin for intravenous use – addition of indication for treatment of parvovirus b19 infection revision of core summary of product characteristics for human plasma derived factor vii products and human plasma prothrombin complex revision of core summary of product characteristics for factor viii inhibitor bypassing fraction warning on transmissible agents for patient leaflets and summary of product characteristics revision of core summary of product characteristics for human anti- d immunoglobulin for intravenous and/ or intramuscular